Omixon is a global biotechnology company that commercializes disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.
Join us for a “power hour” Basic and Advanced workshop series at this year’s ASHI Meeting in Savannah. The Omixon Academy Training Series is ABHI approved and Certificate of Attendance will be available for attendees that stay for the duration …more
The Holotype Early Access Program was formally announced at ASHI 2014 in Denver, and ran until 2015 July. 24 labs across 13 countries have been trained in the use of Holotype HLA and have genotyped hundreds of their own samples. …more